For the treatment of pain and inflammation associated with chronic osteoarthritis in dogs.

For the treatment of pain and inflammation of chronic osteoarthritis in dogs.

The expression of hepatic CYP450 enzymes is suppressed by the cytokines, such as IL 6, that stimulate chronic inflammation.

Sore throat, inflamed sinuses inflammation of the stomach (gastritis)

Sore throat, inflamed sinuses inflammation of the stomach (gastritis)

General side effects chronic lung disease, decreased blood pressure, throat irritation, cough, difficulty sleeping, skin inflammation, redness or itching, runny nose, hair disorder

Information on interactions should be included if relevant and readily available.

hair loss, inflammation of hair follicles, scaly skin, inflammation or rash, abnormal skin

(c) Predicting the interactions between ingredients is extremely difficult, and where information on interactions is not available, assumptions should not be made and instead the health effects of each ingredient should be listed separately.

Other relevant information on adverse health effects should be included even when not required by the GHS classification criteria.

A4.3.12.1 Provide information to evaluate the environmental impact of the substance or mixture if it were released to the environment.

inflamed pancreas

inflammation of pancreas

colitis (bowel inflammation)

flushing, itching and inflamed skin, inflammation of mucus (moist) linings such as the mouth

In dogs, Onsior tablets are used for the treatment of pain and inflammation associated with chronic osteoarthritis (a long term disease causing pain in the joints).

if you have inflammation of the colon (ulcerative colitis) or intestinal tract (Crohn s disease)

It is also used to treat Paget's disease (a chronic disease of the bones characterised by inflammation and deformation), and hypercalcaemia of malignancy (increased dic

Histologically, mild local reactions with chronic inflammation of the connective tissue and some capsule formation and collagen deposition have been seen at 3 months after administration.

(i) stabilizers and

(p) Auto ignition temperature

inflammation of the pancreas (pancreatitis),

injection site inflammation ,

hepatitis,

Very common nausea vomiting diarrhoea an uncomfortable feeling in the stomach or belching after eating Common wind dry mouth acid regurgitation Not known inflammation of the pancreas

Very common nausea vomiting diarrhoea an uncomfortable feeling in the stomach or belching after eating Common wind dry mouth acid regurgitation Not known inflammation of the pancreas 102 Skin and subcutaneous tissue disorders

Inflammation and irritation of the vagina,

inflammation of the pancreas (pancreatitis).

heel

inflammation of the pancreas (pancreatitis).

eye inflammation,

inflammation of the liver (hepatitis)

Solution for injection 5 mg ml 1

pancreatitis

Fever. Inflammation of the lungs.

Chronic Fatigue Syndrome.

II IV GvHD GvHD

Accelerated

Daily dose in mg

If a mixture has not been tested for its health effects as a whole then information on each ingredient listed under A4.3.3.2.1 should be provided and the mixture should be classified using the processes that are described in the GHS (Section 1.3.2.3 and subsequent chapters).

(b) if it is unlikely that these effects will occur at the concentrations present.

A4.3.12 SECTION 12 Ecological information

Chronic suppurative otitis media

SF(chronic) xafety factor for chronic toxicity.

SF (chronic) Safety factor for chronic toxicity.